News & Events · May 8, 2025 Yamo Pharma Presents Statistically Significant Phase 2 Autism Results for L1-79 at INSAR 2025 https://www.globenewswire.com/news-release/2025/05/08/3077235/0/en/Yamo-Pharma-Presents-Statistically-Significant-Phase-2-Autism-Results-for-L1-79-at-INSAR-2025.html
News & Events · July 31, 2024 Yamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of Autism https://www.globenewswire.com/news-release/2024/07/30/2920974/0/en/Yamo-Pharmaceuticals-Announces-Positive-Topline-Results-from-Phase-2-Study-of-L1-79-for-the-Treatment-of-the-Core-Symptoms-of-Autism.html
News & Events · January 27, 2022 Yamo Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study of L1-79 in Autism Spectrum Disorder https://www.globenewswire.com/news-release/2022/01/27/2374277/0/en/Yamo-Pharmaceuticals-Announces-Enrollment-of-First-Patient-in-Phase-2-Study-of-L1-79-in-Autism-Spectrum-Disorder.html
